Ed with HE staining. The optimistic rate of 70 was determined as overexpression of p53 protein. The KRAS genotype of the tumor samples was analyzed making use of the Luminex assay, as previously reported [8]. The sensitivity of KRAS testing by Luminex has been reported to become ten [9].Osumi et al. BMC Cancer (2015) 15:Web page three ofTable 1 Patients characteristicsITT popuration (n = 90) p53 antibody Constructive (n = 36) Gender, n ( ) Male Female Age Median (range) 65, n ( ) 65, n ( ) ECOG PS at base line, n ( ) 0 33(91.six) 1 3(eight.3) Liver metastasis, n ( ) 12(33.3) Lung metastasis, n ( ) 12(33.3) Lymph node metastasis, n ( ) 21(66.six)ITT intention to treat, PS overall performance statusKRAS wild sort p53 antibody Good (n = 11) 9(81.eight) two(18.1) Adverse (n = 31) 16(51.6) 15(48.three)KRAS mutant p53 antibody Optimistic (n = 13) 9(69.2) four(30.7) Adverse (n = 13) eight(61.five) five(38.4)Adverse (n = 54) 30(55.5) 24(44.four)25(69.4) 11(30.five)58.four(394) 26(72.2) 10(27.7)60.9(395) 31(59.2) 23(42.5)57.3(413) eight(72.7) 3(27.two)59.eight(391) 19(61.two) 12(38.7)59.three(394) 9(69.two) four(30.7)61.three (415) 6(46.1) 7(53.8)51(94.four) three(5.5) 31(57.4) 22(40.7) 26(48.1)11(100) 0(0) 7(63.six) five(45.four) eight(72.7)30(96.7) 1(3.1) 19(61.2) 9(29.0) 17(54.eight)9(69.2) 3(23.0) 3(23.0) 4(30.7) 8(61.5)12(92.3) 1(7.7) five(38.4) eight(61.five) 4(30.7)Statistical analysisPercentages were compared applying the chi-square or Fisher’s precise test when suitable. Quantitative variables had been compared employing Student’s t test. Follow-up was estimated utilizing the Kaplan-Meier approach. The correlation among p53 antibody and also the KRAS genotype, IHC of p53 protein had been estimated employing Pearson’s correlation coefficient. OS and PFS have been estimated applying the Kaplan-Meier technique and compared employing the log-rank test. PFS was defined as the interval beginning with chemotherapy to relapse or death, whichever occurred first. Variables connected with OS or PFS with a P worth 0.two in a univariate analysis had been incorporated within a multivariate ascending stepwise Cox regression evaluation. In the Cox model, continuous variables had been dichotomized.Table 2 Clinical response soon after 1st line chemotherapyITT popuration (n = 90) p53 antibody Good n ( ) Complete Response Partial Response (PR) Steady Illness Progressive Illness Not Evaluable PR in Odds ratio (95 CI) P value n = 36 5(13.8) 21(58.3) 5(five.5) two(8.Buy199003-22-0 three) 3(eight.three) 26(72.2) 1.1 (0.55.21) 0.87 Unfavorable (n = 54) 2(3.7) 41(74.0) ten(18.five) 1(1.8) 0(0) 43(79.six)All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing). All reported P values had been two-sided, and P values 0.05 have been thought of important.ResultsPatients traits (Table 1)Among January 2009 and November 2010, 90 individuals were referred for first-line chemotherapy for mCRC.Buy1131912-76-9 Median age with the individuals in the time of measuring antip53 antibody was 61 years old (.PMID:30125989 1). This cohort was composed of males (38.8 ) and females (61.2 ). Serum anti-p53 antibodies had been detected in 40.0 individuals (36/ 90). IHC analyzed with monocloncal antibodies againstKRAS wild sort p53 antibody Optimistic (n = 11) 1(9) 9(81.8) 1(9) 0(0) 0(0) 10(91) 0.92 (0.three.eight) 1 Adverse (n = 31) 1(3.2) 25(80.six) 3(9.7) 1(3.two) 1(3.two) 26(83.eight)KRAS mutant p53 antibody Constructive (n = 13) 3(23) 7(53.eight) 3(23) 0(0) 0(0) ten(76.9) 0.9 (0.23.43) 1 Negative (n = 13) 0(0) 9(69.2) 4(30.7) 0(0) 0(0) 9(69.two)Osumi et al. BMC Cancer (2015) 15:Page four ofFig. 1 Overall survival and progression-free survi.
